TBPH FY 2012 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$685M

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$130M+776.2% YoY

Gross Profit

$16M12.4% margin

Operating Income

-$10M-7.4% margin

Net Income

-$10M-7.4% margin

EPS (Diluted)

$-0.30

Cash Flow

Operating Cash Flow

-$119M

Free Cash Flow

-$122M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$21M

Total Liabilities

$23M

Stockholders' Equity

-$7M

Cash & Equivalents

$0

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$130M	$15M	+776.2%
Gross Profit	$16M	$11M	+46.7%
Operating Income	-$10M	-$109M	+91.2%
Net Income	-$10M	-$109M	+91.2%